PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2006
CASE
AUTH/1829/4/06 Allergan ⭐ Case of the Week

Doctor v Allergan (AUTH/1829/4/06): Vistabel POM advert in Aesthetic Medicine – no breach

A doctor alleged a Vistabel (POM) ad appeared in a journal accessible to non-HCPs. The Panel held the publication was aimed at…

2007
CASE
AUTH/2035/8/07 Leo

Leo Pharmaceuticals: Dovobet β€˜Dear Doctor’ letter implied most patients could be switched from Dovonex (AUTH/2035/8/07)

A β€˜Dear Doctor’ letter said Dovobet could replace Dovonex for β€œthe majority” of patients, without clearly explaining key differences (incl. potent steroid…

2007
CASE
AUTH/2015/7/07 Bayer

AUTH/2015/7/07: Lilly v Bayer Schering Pharma – Levitra claims β€˜works first time’ and β€˜many men prefer’ ruled misleading

Lilly challenged Levitra ad/leavepiece claims including β€œWorks first time in 9 out of 10 men”, β€œwine and dine”, and β€œmany men prefer”.…

2019
CASE
Mundibiopharma

Mundibiopharma breached ABPI Code over Invokana virtual booth email: incomplete prescribing information, misleading non-significant outcomes claims, and uncertified linked papers

Invokana virtual booth email/microsite breached the Code for incomplete prescribing info, misleading headline claims implying significance, missing Vokanamet generic name, and failure…

2006
CASE
AUTH/1910/11/06 GlaxoSmithKline

Sanofi Pasteur MSD v GlaxoSmithKline (AUTH/1910/11/06): Cervical cancer disease awareness team ruled to be pre-licence promotion on appeal

GSK’s UK cervical cancer disease awareness field team was initially cleared, but on appeal the cumulative arrangements were ruled to promote an…

2019
CASE
AUTH/3173/3/19 Novo Nordisk ⭐ Case of the Week

Novo Nordisk: Undeclared employee shareholdings created potential conflict of interest (Saxenda) (AUTH/3173/3/19)

Anonymous HCP alleged Saxenda was being sold/promoted to the public via linked companies. Panel found no evidence Novo Nordisk was involved, but…

2009
CASE
AUTH/2284/12/09 Norgine

AUTH/2284/12/09: Anonymous Nurse v Norgine β€” No breach (outwith scope of the Code)

PMCPA case AUTH/2284/12/09 (Anonymous Nurse v Norgine): no breach found because the matter was outwith the scope of the ABPI Code. Undertaking…

2011
CASE
AUTH/2419/7/11 Boehringer Ingelheim

AUTH/2419/7/11: Publisher/Editor v Boehringer Ingelheim (Mirapexin/Sifrol tweet) β€” No breach (outwith scope)

Complaint about a Mirapexin/Sifrol tweet. PMCPA recorded no breach because the matter was outwith the scope of the Code. Undertaking received; no…

2018
CASE
AUTH/3054/7/18 PharmaMar

PharmaMar: Madrid meeting hospitality judged out of proportion despite being within Spanish meal limit (AUTH/3054/7/18)

Anonymous complaint about a Madrid meeting: a pre-meeting β€œgala dinner” created a lavish impression and was ruled not secondary to the meeting’s…

2019
CASE
AUTH/3142/1/19 Sanofi

Sanofi: Praluent advertorial on HSJ website found not to be promotion to the public (AUTH/3142/1/19)

Complaint about a Praluent advertorial on the HSJ website alleged it was unsuitable for public access and links/references were problematic. The PMCPA…

2018
CASE
AUTH/3021/2/18 Shire ⭐ Case of the Week

AUTH/3021/2/18: Anonymous v Shire β€” Meeting advertised on LinkedIn (No breach; outwith scope)

Anonymous complaint about a Shire meeting advertised on LinkedIn. PMCPA concluded no breach because the matter was outwith the scope of the…

2019
CASE
AUTH/3278/11/19 Strides Pharma UK

Strides Pharma UK Ltd breached ABPI Code over β€˜The Licensed Vitamin D3 of Choice’ claim for Strivit-D3 (AUTH/3278/11/19)

A MIMS print ad for Strivit-D3 used β€˜The Licensed Vitamin D3 of Choice’. PMCPA ruled it implied first-choice status and was misleading/exaggerated…

2019
CASE
A Menarini

A Menarini breached Clause 12.1 after PDF supplement lacked clear upfront company involvement (Ranexa case study)

Guidelines in Practice-hosted Ranexa case study wasn’t disguised online, but the downloadable PDF didn’t clearly show Menarini involvement on the front page,…

2020
CASE
AUTH/3328/4/20 GlaxoSmithKline

GSK breached ABPI Code after Avamys digital banner showed illegible generic name (AUTH/3328/4/20)

An anonymous UK health professional complained Avamys’ generic name was unreadable in a Pulse website banner. PMCPA found breaches of Clauses 4.3…

2019
CASE
Vifor Pharma

Vifor Ferinject website: open-access landing page promoted a POM to the public and β€œsimple to administer” claim found misleading

PMCPA ruled Vifor’s Ferinject site landing page promoted a POM to the public (Clause 26.1) and an HCP claim that Ferinject was…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training